84499-77-4

Usage

Uses

Used in Pharmaceutical Research and Development:
1-(4-Bromophenyl)ethylamine hydrochloride is used as a research compound for the development of new drugs targeting the central nervous system. Its psychoactive properties make it a valuable tool in understanding the mechanisms of action and potential therapeutic effects of drugs in this area.
Used in Neurological and Psychiatric Disorder Treatment:
1-(4-Bromophenyl)ethylamine hydrochloride is used as a potential therapeutic agent for the treatment of various neurological and psychiatric disorders. Its psychoactive properties suggest that it may have beneficial effects on cognitive functions and behavior, making it a promising candidate for further research and development in this field.
Used in Scientific Studies:
1-(4-Bromophenyl)ethylamine hydrochloride is used as a subject of interest in scientific studies to explore its potential effects on behavior and cognitive functions. Understanding the mechanisms of action of 1-(4-Bromophenyl)ethylamine hydrochloride can provide valuable insights into the development of new treatments and interventions for neurological and psychiatric conditions.

InChI:InChI=1/C8H10BrN.ClH/c1-6(10)7-2-4-8(9)5-3-7;/h2-6H,10H2,1H3;1H

Upstream product

• 1438984-03-2 (S)-N-((S)-1-(4-bromophenyl)ethyl)-2-methylpropane-2-sulfinamide 
• 1039750-63-4 (S,E)-N-(1-(4-bromophenyl)ethylidene)-2-methylpropane-2-sulfinamide 
• 99-90-1 para-bromoacetophenone 
• 911372-48-0 (R_S)-N-(1-(4-bromophenyl)ethylidene)-2-methylpropane-2-sulfinamide 
• 911372-67-3 (R_S)-N-((S)-1-(4-bromophenyl)ethyl)-2-methylpropane-2-sulfinamide 

Downstream Products

• 847728-90-9 (S)-methyl 4-(1-((tert-butoxycarbonyl)amino)ethyl)benzoate 
• 1380754-50-6 (S)-methyl 4-(1-(5-chloro-2-(3-(4-fluorophenoxy)azetidin-1-yl)nicotinamido)ethyl)benzoate 
• 847728-89-6 (S)-tert-butyl (1-(4-bromophenyl)ethyl)carbamate 
• 494773-21-6 (S)-4-(1-(4-bromophenyl)ethyl)morpholine 

Relevant academic research and scientific papers

N-BENZYLBENZIMIDAZOLE MODULATORS OF PPARG

The invention provides molecular entities that bind with high affinity to PPARG (PPAR?), inhibit cdk5-mediated phosphorylation of PPARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes or obesity. Methods of preparation of the compounds, bioassay methods for evaluating compounds of the invention as non-agonistic PPARG binding compounds, and pharmaceutical compositions are also provided.

N-BIPHENYLMETHYLBENZIMIDAZOLE MODULATORS OF PPARG

The invention provides molecular entities that bind with high affinity to PPARG (PPAR?), inhibit cdk5-mediated phosphorylation of PPARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes or obesity. Methods of preparation of the compounds, bioassay methods for evaluating compounds of the invention as non-agonistic PPARG binding compounds, and pharmaceutical compositions are also provided.

[1, 2, 4] TRIAZOLO [1, 5-A] PYRIDINES AS JAK INHIBITORS

Novel [1,2,4]triazolo[1,5-a]pyridine compounds are disclosed that have a Formula represented by the following: (I). The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, joint disease, inflammation, and others.

Reversal of diastereofacial selectivity in hydride reductions of N-tert-butanesulfinyl imines

A variety of N-tert-butanesulfinyl imines were reduced with NaBH 4 in THF containing 2% water to provide the corresponding secondary sulfinamides in high yield and diastereoselectivity. By using the same sulfinyl imine starting materials and changing the reductant to L-Selectride, the stereoselectivity could be efficiently reversed to afford the opposite product diastereomer in high yield and selectivity.